WEED, INC.
For the period ended Dec 31, 2025. Filed Apr 8, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 8, 2026
BUDZStored price and day change unavailable
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-K
Period ended 2024-12-31; filed 2025-03-31.
0001096906-25-000350
ITEM 7. – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONCurrent report: 10-K
Period ended 2025-12-31; filed 2026-04-08.
0001096906-26-000507
ITEM 7. – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 51 previous paragraphs and 51 current paragraphs.
27 unchanged; 12 reworded; 12 added; 12 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 2 previous and 2 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (12)
Current report
WEED, Inc. (the “Company”) is a multi-national bio-pharmaceutical and real estate holding company. Our mission is to lead the development and application of cannabis-derived compounds for medical and industrial use. During fiscal 2025, the Company focused on asset preservation and the modernization of its business model, which included streamlining international operations and exploring the integration of blockchain and AI technologies within the regulated cannabis ecosystem.
Current report
Key Material Events of 2025
Current report
Research and Intellectual Property Development
Current report
The Company continues to integrate assets from the Hempirical Genetics, LLC acquisition. This includes a proprietary seedbank of over 250 cannabis and hemp strains, featuring rare Landrace varieties such as Panama Red and Acapulco Gold. Throughout 2025, management focused on cataloging these genetics to support future pharmaceutical research and consumer product strategies. These genetic assets are currently carried at a cost basis on our balance sheet, though management believes they represent significant long-term strategic value as the federal regulatory environment for cannabis evolves.
Current report
Strategic Technology Initiatives
Current report
In December 2025, the Company entered into a strategic partnership with Remergify, Inc. to evaluate the development of a digital asset ecosystem. This project aims to address banking and supply chain challenges through the potential launch of WEEDCoin and BUDZCoin. These initiatives are currently in the early development phase. The Company’s ability to successfully launch these digital assets is subject to the availability of capital and the complex, evolving regulatory framework governing digital assets and decentralized finance.
Current report
Real Estate Assets and Infrastructure
Current report
A cornerstone of the Company’s stability is its long-term real estate holdings. Management continues to maintain and market its high-value land assets, notably the "Four Winds of Lake Erie" property in Portland, New York. This 44-acre parcel, featuring significant lake frontage, represents a key "hard asset" that distinguishes the Company from peers in the microcap sector. These properties are held to provide the Company with a tangible asset base while management pursues its broader bio-pharmaceutical goals.
Current report
Licensing and Regulatory Compliance
Current report
Through its wholly-owned subsidiary, HEMP BioSciences Inc., the Company maintained its comprehensive suite of industrial hemp licenses in Arizona, including cultivation, nursery, and processing permits. Additionally, in late 2025, the Company successfully completed the de-registration of its non-essential international subsidiaries, WEED Hong Kong Ltd. and WEED Australia Ltd. This repatriation of assets and intellectual property to the U.S. parent company was a strategic move to reduce overhead and simplify the corporate governance structure.
Current report
Results of Operations for the Years Ended December 31, 202****5 and 2024
Current report
For the year ended December 31, 2025 and 2024, we had no cash flows provided from investing activities.
Removed paragraphs (12)
Previous report
Currently, WEED and its subsidiaries are working on or planning for several different business opportunities in the cannabis & hemp field, including, but not limited to: both indoor and outdoor “grows”, cultivations & harvest for research, product development, processing and manufacturing of both Pharma & non-Pharma products, services, therapeutics, and treatments on a global basis for both the Medical Cannabis & Hemp (<.03 thc) global market space. Long terms goals include hopeful cures for many diseases and ailments for both man & animals utilizing the Cannabaceae plant and its derivatives. We will need additional financing to attempt to accomplish these goals.
Previous report
Second, on November 22, 2021, WEED completed the purchase of the Sugar Hill Golf course property located in the town of Portland, New York. WEED’s acquisition of this ~43 acre property with ~2000 ft. of Lake Erie waterfront also comes with the “unlimited water extractions rights” from Lake Erie related to the property, along with a complete wastewater management plant. WEED’s initial plan is to utilize the property to access the hemp and infused beverage markets as our property in the middle of the largest concord grape producing region of the United States. In the future, WEED may look to use the unique property infrastructure to build a luxury condos & resort development in the most natural settings to be ESG compliant in conjunction to WEEDs forming its Social Equity Advisory Council (SEAC) to create Diversity & Equality in our industry. This project is only in its conceptual stage, no funding or plans have been developed other than the proposed name: The 4 Winds Luxury condos & resort to be “Cannabis Friendly” which would be a “FIRST” in the nation.
Previous report
Third, WEED established WEED Australia Ltd. and its wholly owned Cannabis Institute of Australia (C.I.A.) in Australia in March of 2017, for the purpose of conducting cannabis and hemp research and potentially developing products and educational services in and for Australians as stated above. C.I.A. is a non-profit entity formed for the purpose of conducting cannabis and hemp research with universities and other non-profits to protect all intellectual rights, properties and usage in our highly regulated industry. The C.I.A. has the potential to develop products in Australia for domestic research and development of products, services and educational purposes to all seven States and territories, including Tasmania, to be marketed globally.
Previous report
Corporate Overview
Previous report
We were originally incorporated under the name Plae, Inc., in the State of Arizona on August 20, 1999. At the time we operated under the name Plae, Inc., no business was conducted. No books or records were maintained and no meetings were held. In essence, nothing was done after incorporation until Glenn E. Martin took possession of Plae, Inc. in January 2005. On February 18, 2005, the corporate name was changed to King Mines, Inc. and then subsequently changed to its current name, United Mines, Inc., on March 30, 2005. No shares were issued until the Company became United Mines, Inc. From 2005 until 2015, we were an exploration stage mineral exploration company that owned a number of unpatented mining claims and Arizona State Land Department claims.
Previous report
On November 26, 2014, our Board of Directors approved the redomestication of our company from Arizona to Nevada (the “Articles of Domestication”), and approved Articles of Incorporation in Nevada, which differed from then-Articles of Incorporation in Arizona, primarily by (a) changing our name from United Mines, Inc. to WEED, Inc., (b) authorizing Twenty Million (20,000,000) shares of preferred stock, with blank check rights granted to our Board of Directors, and (c) authorizing Two Hundred Million (200,000,000) shares of common stock (the “Nevada Articles of Incorporation”). On December 19, 2014, the holders of a majority of our outstanding common stock approved the Articles of Domestication and the Nevada Articles of Incorporation at a Special Meeting of Shareholders. On January 16, 2015, the Articles of Domestication and the Nevada Articles of Incorporation went effective with the Secretary of State of the State of Nevada. On February 2, 2015, our name change to WEED, Inc., and a corresponding ticker symbol change to “BUDZ” went effective with FINRA and was reflected on the quotation of our common stock on OTC Markets.
Previous report
These changes were affected in order to make our corporate name and ticker symbol better align with our short-term and long-term business focus. Our current, short-term goals relate to the Cannabis Genomic Study and the resulting development of a variety of new cannabis strains, and, over the next 5 years, we plan to process those results in order to become an international cannabis research and product development company, with a globally-recognized brand focusing on building and purchasing labs, land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to universities, state governments, licensed dispensary owners and organic grow operators on a contract basis with a concentration on the legal and medical cannabis sector.
Previous report
Our long-term plan is to become a true “Seed-to-Sale” global holding company providing infrastructure, financial solutions, product development, and real estate options in this new emerging market. Our long term growth may also come from the acquisition of synergistic businesses, such as distilleries, to make anything from infused beverages to super oxygenated water with CBD and THC. Currently, we have formed WEED Australia Ltd., registered as an unlisted public company in Australia to address this Global demand. We have also formed WEED Israel Cannabis Ltd., an Israeli corporation, to address future global demand. We will look to conduct future research, marketing, import/exporting, and manufacturing of our proprietary products on an international level.
Previous report
On April 20, 2017, we entered into a Share Exchange Agreement with Sangre AT, LLC, a Wyoming limited liability company, under which we acquired all of the issued and outstanding limited liability company membership units of Sangre in exchange for Five Hundred Thousand (500,000) shares of our common stock, restricted in accordance with Rule 144. As a result of this agreement, Sangre is a wholly-owned subsidiary of WEED, Inc..
Previous report
Gain on Disposal of Fixed Assets
Previous report
During the year ended December 31, 2023, we had gain disposal of fixed assets of $988,375, compared to nil in the year ended December 31, 2024.. The gain on disposal of fixed assets in 2023 relates to the sale of company-owned residential property near La Veta, Colorado.
Previous report
For the year ended December 31, 2024, we had cash flows provided by investing activities of nil, compared to cash flows from investing activities of $1,631,073, primarily from $1,641,073 in proceeds from disposal of fixed assets, offset by $(10,000) related to purchase of property and equipment for the year ended December 31, 2023.
Reworded paragraphs (12)
Previous wording
Our first business opportunity was, and continues to be, through our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), where we are focused on the development and application of cannabis-derived compounds for the treatment of human disease and animal ailments. To that end Sangre, was working on a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic classification of the entire plant. Sangre completed a 1-2 year Pilot Study in 2017 & 2018 at the University of Texas-Galveston thru Industrial Metagenomics at a cost of nearly $1 million USD. Sangre completed the pilot study with 30 cultivars from strains collected worldwide that included 30 strains (twenty-four female and six male). These results are highly proprietary and the basis of future studies to come. We need to raise additional funds to continue the next steps in our Cannabis Genomic Study.
Current wording
Our first business opportunity was, and continues to be, through our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), where we are focused on the development and application of cannabis-derived compounds for the treatment of human disease and animal ailments. To that end Sangre, was working on a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic classification of the entire plant. Sangre completed a 1-2 year Pilot Study in 2017 & 2018 at the University of Texas-Galveston through Industrial Metagenomics at a cost of nearly $1 million USD. Sangre completed the pilot study with 30 cultivars from strains collected worldwide that included 30 strains (twenty-four female and six male). These results are highly proprietary and the basis of future studies to come. We need to raise additional funds to continue the next steps in our Cannabis Genomic Study.
Previous wording
Our comprehensive net loss increased by $483,936, from ($25,981) to ($509,917), from the year ended 2023 compared to 2024. Our operating loss decreased by $230,321, from ($770,568) to ($592,992) for the same period. The increase in comprehensive net loss is primarily a result of the fact we had a one-time gain on disposal of fixed assets of $988,375 in 2023 that we did not have in 2024. The decrease in operating loss is primarily a result of decreases in general and administrative expenses and professional fees. These changes are detailed below.
Current wording
Our comprehensive net loss increased by $861,098, from ($509,917) to ($1,371,015), from the year ended 2024 compared to 2025. Our operating loss increased by $797,687, from ($529,992) to ($1,327,679) for the same period. The increase in comprehensive net income is primarily a result of an increase in general and administrative expenses and professional fees in 2025 compared to 2024.
Previous wording
General and administrative expenses decreased by $43,501, from $394,617 for the year ended December 31, 2023 to $351,116 for the year ended December 31, 2024, primarily due to decreases in our consulting services and salary.
Current wording
General and administrative expenses increased by $776,978, from $351,116 for the year ended December 31, 2024 to $1,128,094 for the year ended December 31, 2025, primarily due to increases in our salaries.
Previous wording
Our professional fees decreased by 167,269 during the year ended December 31, 2024 compared to the year ended December 31, 2023. Our professional fees were $156,290 for the year ended December 31, 2024 and $323,559 for the year ended December 31, 2023. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors. We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.
Current wording
Our professional fees increased by $20,808 during the year ended December 31, 2025 compared to the year ended December 31, 2024. Our professional fees were $177,098 for the year ended December 31, 2025 and $156,290 for the year ended December 31, 2024. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors. We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.
Previous wording
During the year ended December 31, 2024, we had depreciation and amortization of $22,586, compared to $52,392 in the year ended December 31, 2023. The depreciation and amortization expense primarily relates to our properties and trademark acquisitions.
Current wording
During the year ended December 31, 2025, we had depreciation and amortization of $22,487, compared to $22,586 in the year ended December 31, 2024. The depreciation and amortization expense primarily relates to our properties and trademark acquisitions.
Previous wording
Interest expense decreased to ($15,325) from ($45,374) for the year ended December 31, 2024 compared to the same period in 2023. Our interest expense primarily relates to notes payable from attorneys and related parties.
Current wording
Interest expense increased to ($43,857) from ($15,325) for the year ended December 31, 2025 compared to the same period in 2024. Our interest expense primarily relates to notes payable from attorneys and related parties.
Previous wording
During the years ended December 31, 2024 and 2023, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of December 31, 2024 was $159,355 and our monthly cash flow burn rate was approximately $45,000. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.
Current wording
During the years ended December 31, 2025 and 2024, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of December 31, 2025 was $33,130 and our monthly cash flow burn rate was approximately $10,500. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.
Previous wording
Our total assets decreased by $165,696 as of December 31, 2024 as compared to December 31, 2023. The decrease in our total assets between the two periods was attributed to decreases in our cash, ROU assets and accumulated depreciation.
Current wording
Our total assets decreased by $178,460 as of December 31, 2025 as compared to December 31, 2024. The decrease in our total assets between the two periods was attributed to decreases in our cash, ROU assets and increased accumulated depreciation.
Previous wording
Our current liabilities and total liabilities increased by $310,619, as of December 31, 2024 as compared to December 31, 2023. This increase was primarily due to increases in notes payable, related parties.
Current wording
Our current liabilities and total liabilities increased by $288,895, as of December 31, 2025 as compared to December 31, 2024. This increase was primarily due to increases in notes payable, related parties.
Previous wording
We had cash available of $159,355 and $290,409 as of December 31, 2024 and December 31, 2023, respectively. Based on our lack of revenue, our cash on hand and current monthly burn rate of approximately $45,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.
Current wording
We had cash available of $33,130 and $159,355 as of December 31, 2025 and December 31, 2024, respectively. Based on our lack of revenue, our cash on hand and current monthly burn rate of approximately $10,500, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.
Previous wording
We had net cash used in operating activities of $(415.524) for the year ended December 31, 2024, as compared to $(1,074,087) for the year ended December 31, 2023. For the period in 2024, the net cash used in operating activities consisted primarily of our net loss of $(510,716), adjusted by depreciation and amortization of $22,586, debt discount amortization of $10,255, and estimated fair value of stock based compensation and shares issued for services of $20,000 and 14,000, respectively. For the period in 2023, the net cash used in operating activities consisted primarily of our net loss of ($31,557), gain on disposal of fixed asset of $(988,375), adjusted by depreciation and amortization of $52,392, debt discount amortization of $14,545, estimated fair value of shares issued for services of $90,000, and imputed interest on RP loans of $21,494, and further adjusted by increases in assets related to prepaid expenses and deposits of $(3,228), and decreases in liabilities consisting of accounts payable of $6,214 and accrued expenses of $223,144.
Current wording
We had net cash used in operating activities of $(195,136) for the year ended December 31, 2025, as compared to $(415,524) for the year ended December 31, 2024. For the period in 2025, the net cash used in operating activities consisted primarily of our net loss of $(1,372,206), adjusted by depreciation and amortization of $22,487, debt discount amortization of $10,255, and estimated fair value of stock based compensation and shares issued for services of $800,000 and 90,000, respectively decreases in assets related to prepaid expenses and deposits of $15,961, and increases in liabilities consisting of accounts payable of $12,362 and accrued expenses of $209,963. For the period in 2024, the net cash used in operating activities consisted primarily of our net loss of ($510,716), adjusted by depreciation and amortization of $22,586, debt discount amortization of $10,255, estimated fair value of stock based compensation and shares issued for services of $20,000 and 14,000, respectively, and further adjusted by imputed interest on RP Loans of $1,200, increases in assets related to prepaid expenses and deposits of $(1,059), and decreases in liabilities and an increase in accrued expenses.
Previous wording
Our net cash provided by financing activities for the year ended December 31, 2024 was 285,269, compared to $(587,979) for the year ended December 31, 2023. For the period in 2024, our financing activities related to proceeds from notes payable of $310,000, partially offset by proceeds from repayments of notes payables-related party of $30,000. For the period in 2023, our financing activities related to proceeds from notes payable of $50,000, offset by repayments of notes payable-related party of $637,979.
Current wording
Our net cash provided by financing activities for the year ended December 31, 2025 was 70,103, compared to $285,269 for the year ended December 31, 2024. For the period in 2025, our financing activities related to proceeds from notes payable of $199,403, partially offset by proceeds from repayments of notes payables-related party of $130,000. For the period in 2024, our financing activities related to proceeds from notes payable of $310,000, offset by repayments of notes payable-related party of $30,000.